SynthesisFrontiers in oncology2026
Percutaneous microwave ablation of hyperfunctioning parathyroid lesions under multiparametric ultrasound guidance for primary hyperparathyroidism: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiparametric ultrasound (MPUS)-guided percutaneous microwave ablation (MWA) has emerged as a minimally invasive treatment option for primary hyperparathyroidism (PHPT), but pooled evidence on longitudinal biochemical outcomes and safety remains limited. Objective: This meta-analysis aimed to evaluate the efficacy and safety of percutaneous MWA performed under ultrasound guidance for PHPT. Methods: Following PRISMA guidelines, eligible cohort studies were retrieved from five electronic databases. Pooled cure rates, serial changes in intact parathyroid hormone (iPTH), serum calcium and phosphorus, overall complication rates, and adenoma volume reduction were calculated via random-effects models. Leave-one-out sensitivity analyses were performed to assess the robustness of the pooled estimates. Results: Nine cohorts enrolling 355 PHPT patients were included. Technical success was 100%. Pooled clinical cure rates reached 86.0% at 6 months, 82.0% at 12 months, and 75.0% at the last available follow-up. Serum calcium and iPTH declined significantly, and serum phosphorus rose across all time points. The pooled patient-level overall complication rate was 11.0%, with transient hoarseness and transient hypocalcemia being the most commonly reported event-specific complications, whereas permanent recurrent laryngeal nerve injury was rare. Conclusion: Current evidence suggests that percutaneous MWA performed under ultrasound guidance may be a minimally invasive treatment option for appropriately selected patients with PHPT, providing acceptable mid-term biochemical improvement with a tolerable safety profile. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025644973, identifier CRD42025644973.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.